FrostPharma AB
ABActiveOrg 5568141708Berga Backe 2, 182 53 DanderydActivities of agents involved in the wholesale of other particular products· NACE 4618Est. 2010 · 16 years old31 employees
Loading company…
Overview
FrostPharma AB is a Swedish AB based in Danderyd, operating in the Activities of agents involved in the wholesale of other particular products sector. Incorporated in 2010, the company has 31 employees and reported revenue of SEK 412.0k in its latest annual filing.
Revenue 2025
412K SEK
−100% vs 2024
EBITDA margin
13.4 %
−100% vs 2024
Net profit 2025
13.7K SEK
-100% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
47.0 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.9×
AverageAround the average of companies in the same industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
3.2 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
SEK millionsKey figures
Annual report 2025| Revenue | 412K SEK | -100% |
| EBITDA | 55K SEK | -100% |
| Net profit | 13.7K SEK | -100% |
| Total assets | 423.6K SEK | -100% |
| Equity | 199K SEK | -100% |
| Employees | 31 | — |
Company information
Legal name
FrostPharma AB
Org number
5568141708
Legal form
Aktiebolag
Founded
7 July 2010 · 16 years
Share capital
SEK 60
Employees
31 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av Nilsson, Lena Louise Willén, Erik Karl-Johan i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolagets verksamhet ska vara att bedriva försäljning, marknadsföring, agentur samt distribution av läkemedel och medicintekniska produkter jämte därmed förenlig verksamhet.
(no translation available)
Contact
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), FrostPharma AB reported revenue of SEK 412.0k, a decrease of 100% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of SEK 13.7k, and the EBITDA margin stood at 13.4%.
At the end of 2025, equity financed 47% of the balance sheet, and current assets covered short-term debt 1.9 times.
Financials
Revenue
SEK millionsEBITDA
SEK millionsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 412 | 275,070 | 183,010 | 139,364 | 79,206 |
| Staff expenses | -39 | — | -25,041 | — | — |
| EBITDA | 55 | 47,679 | 18,301 | 31,106 | -3,642 |
| Depreciation & amort. | -28 | -5,518 | -1,460 | -664 | -14 |
| EBIT | 27 | 42,161 | 16,841 | 30,442 | -3,656 |
| Net financials | -7 | -5,926 | -2,836 | -2,132 | -1,914 |
| Profit before tax | 20 | 27,334 | 10,455 | 22,536 | -5,480 |
| Tax | -6 | -5,804 | 2,314 | -3,590 | -0 |
| Net profit | 14 | 21,530 | 8,141 | 18,946 | -5,480 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 424 | 388,185 | 127,197 | 100,238 | 60,925 |
| Equity | 199 | 194,411 | 34,881 | 26,740 | 6,630 |
| Long-term debt | 88 | 99,009 | 39,262 | 0 | 0 |
| Short-term debt | 105 | 76,541 | 43,730 | 67,724 | 54,295 |
| Total debt | 193 | 175,550 | 82,992 | 67,724 | 54,295 |
Financial ratios
5-year trendEBITDA margin
13.4 %
20212025
Equity ratio
47.0 %
AverageAround the average of companies in the same industry
20212025
Return on equity
6.9 %
AverageAround the average of companies in the same industry
20212025
Net profit margin
3.3 %
AverageAround the average of companies in the same industry
20212025
Asset turnover
0.97×
AverageAround the average of companies in the same industry
20212025
Debt / equity
1.13×
AverageAround the average of companies in the same industry
20212025
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 40% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginStrong
Among the 40% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginAverage
Around the average of companies in the same industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Average
Around the average of companies in the same industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Average
Around the average of companies in the same industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 40% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioStrong
Among the 30% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioAverage
Around the average of companies in the same industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery strong
Among the 20% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 10% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioAverage
Around the average of companies in the same industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityAverage
Around the average of companies in the same industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityAverage
Around the average of companies in the same industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtStrong
Among the 40% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery strong
Among the 20% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 40% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverAverage
Around the average of companies in the same industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
KK Chief Auditor | Chief Auditor | 2023 |
CF Chief Executive Officer | Chief Executive Officer | 2026 |
Former (3)
AM Audit | Audit | 2020 – 2023 |
LM Chief Executive Officer | Chief Executive Officer | 2025 – 2026 |
CF Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (8) | ||
RC Board of Directors | Board of Directors | 2024 |
RA Chairman | Chairman | 2020 |
EK Board of Directors | Board of Directors | 2020 |
SC Board of Directors | Board of Directors | 2020 |
CF Board of Directors | Board of Directors | 2020 |
EC Board of Directors | Board of Directors | 2023 |
DM Deputy Board Member | Deputy Board Member | 2022 |
LL Board of Directors | Board of Directors | 2020 |
Former (1)
EC Deputy Board Member | Deputy Board Member | 2020 – 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Priveq Holding VI AB100%
Priveq Investment VI (A) AB55%
FrostPharma AB (this company)Abboxia AB100% ownedFrostGreen AB100% ownedBoard network connections
Board members of FrostPharma AB also hold positions in 362 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Maria Andersson | Audit | 133 companiesMany roles |
| Kajsa Karin Helena Goding | Chief Auditor | 120 companiesMany roles |
| Lena Louise Nilsson | Board of Directors | 29 companiesMany roles |
| Erik Karl-Johan Willén | Board of Directors | 25 companiesMany roles |
| Daniel Mats Filip Nylund | Deputy Board Member | 16 companiesMany roles |
| Eva Charlotta Walde | Board of Directors | 8 companiesMany roles |
| Ebba Cecilia Bröms | Deputy Board Member | 6 companiesMany roles |
| Roger Carl-Gunnar Tapper | Board of Directors | 6 companiesMany roles |
| Sven Christer Ahlberg | Board of Directors | 6 companiesMany roles |
| Carl Fredrik Oskar S Andersch | Chief Executive Officer | 4 companies |
| Clas Fredrik Lindbergson | Chief Executive Officer | 4 companies |
| Lars Magnus Nylén | Chief Executive Officer | 3 companies |
| Rolf Allan Classon | Chairman | 2 companies |
Frequently asked questions
What is the Org number of FrostPharma AB?
FrostPharma AB is registered with Bolagsverket / SCB under Org 5568141708.
What is the revenue of FrostPharma AB?
FrostPharma AB reported revenue of SEK 412.0k in 2025.
How many employees does FrostPharma AB have?
FrostPharma AB employs 31 people as of the latest annual report.
Who is the CEO of FrostPharma AB?
Carl Fredrik Oskar S Andersch is the CEO of FrostPharma AB, in role since 2026.
Who is the chairman of FrostPharma AB?
Rolf Allan Classon chairs the board of FrostPharma AB, in role since 2020.
Where is FrostPharma AB headquartered?
FrostPharma AB's registered address is Berga Backe 2.